Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858364 · ClinicalTrials.gov registry record · Phase 3
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,549
- Enrollment target
NCT00858364 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 2,549 participants.
The verdict
NCT00858364, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,549 participants
- Enrollment target
Study Summary
This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL compared to participants treated with placebo.
Interventions
- DRUG Placebo
- DRUG Darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,549 participants |
| Start Date | 2009-07-17 |
| Est. Completion | 2017-06-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858364
The ClinicalTrials.gov registry entry for NCT00858364 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,549 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00858364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858364 about?
NCT00858364 is a clinical study titled "Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy". This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated t...
What is the current status of trial NCT00858364?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,549 participants. The study started on 2009-07-17. Estimated completion is 2017-06-07.
What interventions are being tested in trial NCT00858364?
The interventions under investigation include: Placebo (DRUG), Darbepoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00858364?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.